DOVA Insider Trading Activity and SEC Form 4 Filings
DOVA insider trading summary
No open-market insider purchases or sales of Dova Pharmaceuticals Inc. (DOVA) have been reported on SEC Form 4 in the past 12 months.
Latest DOVA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 1, 2019 | David Zaccardelli | President & CEO | Sell | $147K (5,275 @ $27.90) |
| Sep 30, 2019 | LEE F MD PhD ALLEN | Chief Medical Officer | Sell | $27K (978 @ $28.00) |
| Sep 30, 2019 | Kevin Laliberte | Sr. VP, Product Development | Sell | $87K (3,100 @ $28.00) |
| Sep 30, 2019 | Mark W Hahn | Chief Financial Officer | Sell | $22K (775 @ $28.00) |
| Sep 30, 2019 | Jason Hoitt | Chief Commercial Officer | Sell | $67K (2,387 @ $28.00) |
| Sep 30, 2019 | Kevin Laliberte | Sr. VP, Product Development | Sell | $17K (596 @ $28.00) |
| Sep 25, 2019 | Kevin Laliberte | Sr. VP, Product Development | Sell | $62K (3,100 @ $20.00) |
| Aug 9, 2019 | Paul B Manning | Director | Buy | $445K (28,062 @ $15.87) |
| Jul 31, 2019 | Kevin Laliberte | Sr. VP, Product Development | Sell | $22K (1,389 @ $15.97) |
| Jul 15, 2019 | Jason Hoitt | Chief Commercial Officer | Sell | $101K (6,680 @ $15.10) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.